Stereotactic body radiotherapy plus lenvatinib and sintilimab with and without transarterial embolization for advanced hepatocellular carcinoma with portal vein tumor thrombus: a dual-center, propensi
6 hours ago
- #immunotherapy
- #hepatocellular carcinoma
- #locoregional therapy
- Study evaluates SBRT plus lenvatinib and sintilimab with/without TAE for advanced HCC with PVTT.
- 204 patients analyzed; TAE group showed longer median PFS (11.0 vs. 6.0 months) and trend toward improved LC.
- No significant difference in OS between TAE and non-TAE groups (19.0 vs. 18.0 months).
- TAE identified as independent predictor of reduced progression risk (HR = 0.52).
- Similar objective response rates and grade ≥3 adverse events between groups.
- Dual LRT with targeted immunotherapy deemed feasible and safe for advanced HCC with PVTT.